University Hospital of Cologne, Germany.
Int J Oral Maxillofac Implants. 2012 Jan-Feb;27(1):146-54.
The principle of guided tissue and bone regeneration has long been established for treating bone and periodontal defects. In addition to nonabsorbable barriers, various collagens have become accepted as membrane materials for separating the graft from soft tissue. However, collagen membranes differ significantly in their barrier function and biocompatibility. The objective of this pilot study was to examine, in vitro and in vivo, a novel native collagen membrane extracted from porcine pericardium.
The morphologic structure of two different native collagen membranes (Remotis, Thommen Medical; Bio-Gide, Geistlich Biomaterials) was examined using a scanning electron microscope. For biocompatibility testing, membranes were incubated with SaOs-2 osteoblastlike cells. After 2 hours, 3 days, and 7 days, proliferation of the cells on the membranes was determined. Evaluation of the biodegradation pattern was performed in a dog model with simultaneous bone augmentation with Bio-Oss (Geistlich Biomaterials) or Cerabone (Botiss Biomaterials) in the lateral anterior maxilla in eight animals with histologic examination after 4, 8, 12, and 24 weeks.
An interconnective pore system was identifiable for Remotis, while Bio-Gide displayed a more fibrous structure. In vitro, Remotis showed considerable cell proliferation, which was significantly superior to that observed with Bio-Gide, especially after 7 days (2,910 ± 1,273 and 707 ± 706, respectively). In vivo, both membranes integrated into the surrounding tissue without any inflammatory reaction. Both membranes allowed early vascularization. However, considerable biodegradation was noted within 4 to 8 weeks with Bio-Gide, while Remotis resorbed generally within the first 8 to 12 week. Both membranes supported underlying bone formation.
Both examined membranes indicate a high level of biocompatibility. Both are resorbed without inflammation within 8 weeks (Bio-Gide) or 12 weeks (Remotis). The compact interconnective pericardium collagen of Remotis may have stabilized the resorption process.
引导组织和骨再生的原理早已确立,用于治疗骨和牙周缺损。除了不可吸收的屏障外,各种胶原蛋白已被接受为将移植物与软组织分离的膜材料。然而,胶原蛋白膜在其屏障功能和生物相容性方面有很大的差异。本初步研究的目的是体外和体内检查一种从猪心包提取的新型天然胶原蛋白膜。
使用扫描电子显微镜检查两种不同的天然胶原蛋白膜(Remotis,Thommen Medical;Bio-Gide,Geistlich Biomaterials)的形态结构。为了进行生物相容性测试,将膜与 SaOs-2 成骨样细胞孵育。孵育 2 小时、3 天和 7 天后,测定细胞在膜上的增殖情况。在 8 只狗的模型中同时进行骨增量,在前侧上颌骨的外侧用 Bio-Oss(Geistlich Biomaterials)或 Cerabone(Botiss Biomaterials)进行,在 4、8、12 和 24 周后进行组织学检查,以评估生物降解模式。
Remotis 具有可识别的互联孔系统,而 Bio-Gide 则显示出更具纤维状的结构。体外,Remotis 显示出相当大的细胞增殖,与 Bio-Gide 相比,尤其是在第 7 天时,增殖更为明显(分别为 2910±1273 和 707±706)。在体内,两种膜都与周围组织整合,没有任何炎症反应。两种膜都允许早期血管化。然而,在 Bio-Gide 中,在 4 至 8 周内观察到大量的生物降解,而 Remotis 则在 8 至 12 周内基本吸收。两种膜都支持下方的骨形成。
两种检查的膜都显示出高度的生物相容性。两种膜都在 8 周(Bio-Gide)或 12 周(Remotis)内无炎症吸收。Remotis 紧凑的互联心包胶原可能稳定了吸收过程。